 |
|
 |
|
| MarketVIEW: Hepatitis B virus vaccines |
|
|
|
Published: January 2016
Hepatitis B virus (HBV) is transmitted by exposure to infectious blood or body fluids by percutaneous or mucosal means. Transmission occurs usually amongst adults exhibiting risk behaviours e.g. IDUs, MSM and heterosexuals with multiple partners although vertical transmission can occur from mother to child at birth. The HBV virus is more infectious than HIV and can cause chronic infection, resulting in cirrhosis of the liver, liver cancer, liver failure, and death. It is estimated that 2 billion people worldwide have been infected with the virus and about 600 000 people die every year due to the consequences of hepatitis B (WHO Figures).
This MarketVIEW is a comprehensive MS Excel-based model + summary presentation which forecasts the potential
commercial value of Hepatitis B Virus (HBV) adult vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all adult risk groups and infants vaccination (where policy in place). The product also includes two different scenarios for the potential penetration of Dynavax's new HBV vaccine Heplisav into US and EU markets and giving estimates of potential revenues to 2030.
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 2 MODELS
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%.
Please review the TERMS and CONDITIONS of purchase.
|
|
|
|
|
|
